These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17848299)

  • 41. [Anti-angiogenic treatment is effective for treating metastatic colorectal cancers].
    Bono P; Joensuu H
    Duodecim; 2004; 120(3):261-2. PubMed ID: 15061003
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiangiogenic drugs in ovarian cancer.
    Kumaran GC; Jayson GC; Clamp AR
    Br J Cancer; 2009 Jan; 100(1):1-7. PubMed ID: 19002176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Taming vessels to treat cancer.
    Jain RK
    Sci Am; 2008 Jan; 298(1):56-63. PubMed ID: 18225696
    [No Abstract]   [Full Text] [Related]  

  • 46. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis.
    Lainer-Carr D; Brahn E
    Nat Clin Pract Rheumatol; 2007 Aug; 3(8):434-42. PubMed ID: 17664950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 49. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
    Sato Y
    Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Value of angiogenesis inhibitors in tumor diseases--preclinical data]].
    Berdel WE; Panse J
    Onkologie; 2005 Oct; 28 Suppl 4():25-8. PubMed ID: 16205102
    [No Abstract]   [Full Text] [Related]  

  • 52. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumoral angiogenesis: review of the literature.
    Khosravi Shahi P; Fernández Pineda I
    Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
    Sitohy B; Nagy JA; Dvorak HF
    Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
    Wachsberger P; Burd R; Dicker AP
    Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular endothelial growth factor pathway.
    Krupitskaya Y; Wakelee H
    J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1071-3. PubMed ID: 19861922
    [No Abstract]   [Full Text] [Related]  

  • 59. The function of vascular endothelial growth factor.
    Nieves BJ; D'Amore PA; Bryan BA
    Biofactors; 2009; 35(4):332-7. PubMed ID: 19415738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.